Curability of solitary bone plasmacytoma.
- 1 April 1992
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 10 (4) , 587-590
- https://doi.org/10.1200/jco.1992.10.4.587
Abstract
PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a myeloma protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple myeloma. When it occurred, progression of myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of myeloma protein with involved-field radiotherapy predicted long-term disease-free surv...Keywords
This publication has 0 references indexed in Scilit: